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Purpose: Premature peripheral vascular disease (PVD), occurring <60 years of age, is associated with significant
cardiovascular morbidity, limb loss, and death. We hypothesized that different risk factors predict the development of
PVD in patients <60 years than in patients >60 years.
Methods: To address this question, we conducted a population-based observational study using the National Health and
Nutritional Survey (NHANES) data set, which represents the noninstitutionalized civilian population in the United
States. From 1999 to 2002, 5083 participants were analyzed as part of the NHANES survey. PVD status was defined by
an ankle-brachial index (ABI) of <0.9. Putative risk factors for the development of PVD were collected by physical
examination, interview, and laboratory testing. Univariate and multivariate logistic regression analyses were used to
evaluate interactions between age strata and the development of PVD.
Results: Premature PVD was found in 2.1%  0.2% of the population <60 years, and PVD was found in 12.0%  0.8%
of the population >60 years. This corresponds to approximately 1.44 million people with premature PVD. Multivariate
analysis determined coronary artery disease (odds ratio [OR] 2.90 vs 1.26, P .083) and elevated serum fibrinogen (OR
1.07 vs 1.03, P  .034) were stronger predictors of PVD in subjects <60 years than in older subjects. Chronic renal
insufficiency (OR 1.02 vs 1.16, P  .006) was more highly predictive of PVD in subjects >60 years. Other significant
predictors, irrespective of age, in the multivariate model included hypertension (OR 1.99, P< .001), smoking (OR 2.22,
P < .001), and serum homocysteine (OR 1.27, P  .067).
Conclusions: Clinicians should be aware of the high risk of developing premature PVD in patients <60 years with
coexisting coronary artery disease or elevated plasma fibrinogen. Routine screening by ABI measurements in high-risk
patients would enhance the detection of subclinical premature PVD and allow for secondary intervention. (J Vasc Surg
2006;44:319-25.)Premature peripheral vascular disease (PVD)60 years
of age is associated with an extremely poor prognosis.1
Affected patients have high rates of cardiovascular morbid-
ity, limb loss, and death.2-4 This early onset of PVD pre-
sumably represents an accelerated development of athero-
sclerosis in these patients. Etiologic factors responsible for
the development of atherosclerosis may be more readily
identified in this younger patient population.
Previous studies have underscored the progressive na-
ture of PVD in younger patients. Among young, white men
(45 years) referred to a Veterans Administration vascular
surgery service, 40% of patients required multiple surgical
interventions or amputation to treat their PVD.2 Addition-
ally, 30% of patients had progression of their coronary
artery disease (CAD), and 17% died5 years of follow-up.
In a related study, an incredibly high prevalence of asymp-
tomatic CAD (71%) was detected by coronary angiography
or noninvasive testing.5 Presumably, the development of
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coronary and peripheral vascular beds at an accelerated rate.
These same investigators also attempted to identify
putative risk factors associated with premature peripheral
vascular disease. They found a strong association with
smoking and family history6 and a serologic association
with elevated serum lipoprotein (a).7 These studies are
compelling, but they suffer from their small sample size and
lack generalizability owing to their highly selected patient
populations.
We have conducted a population-based study to exam-
ine risk factors for the development of premature PVD. For
the purpose of this study, we defined premature PVD as
occurring in the population 60 years of age. We hypoth-
esized that different risk factors identify premature PVD in
patients60 years of age than in older patients. Data from
the National Health and Nutritional Examination Survey
for years 1999-2002 (NHANES 2000) was used to deter-
mine the prevalence of premature PVD in the US popula-
tion. In addition, presumptive risk factors were used as
covariates to model the occurrence of PVD. Interactions
between these risk factors and age (60 years vs60 years)
were used to identify strong predictors of premature PVD.
METHODS
Data sources. NHANES conducts national, cross-
sectional surveys of the noninstitutionalized US popula-
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multistage probability-cluster design. Data collected using
this method are representative of the overall US popula-
tion, allowing a population-based study design.
NHANES incorporates data collected from interview
and examination as well as laboratory data. Beginning in
1999, NHANES has provided a detailed lower extremity
examination, including the measurement of ankle-brachial
indices (ABI), a noninvasive measurement of lower extrem-
ity atherosclerosis. The prevalence of PVD is determined
using the ABI measurement and is correlated with other
collected variables on the sampled population.
Data for this study included the years 1999-2000 and
2001-2002 (NHANES 2000). Files were obtained from
the NHANES Website (http://www.cdc.gov/nchs/
nhanes.htm) and were merged to create a single data set.
ABI measurements. Details of the ABI measurement
procedure can be found on the NHANES Website. All
study participants 40 years were invited to participate in
the lower extremity examination. Exclusion criteria in-
cluded people weighing 400 pounds or with bilateral
amputation. Other reasons for nonparticipation in the
lower extremity exam included (1) casts, ulcers, dressings
or other conditions of the participant interfered with the
testing, (2) participant could not understand the test in-
structions, (3) participant became ill and the test could not
be performed, (4) an equipment failure occurred, (5) the
participant refused, (6) the participant came late or left early
from the mobile examination center (MEC) and the lower
extremity disease (LED) exam could not be performed, or
(7) some other reason.
Supine systolic pressure was measured two times in the
arm (brachial artery) and both ankles (posterior tibial arter-
ies). The ABI was calculated by dividing the systolic blood
pressure at the ankle by the mean systolic blood pressure in
the arm. The higher of the two measurements was used as
the ABI measurement in this study. Peripheral vascular
disease (PVD) was then defined as an ABI 0.9. This
definition conforms to accepted standards of reporting for
peripheral vascular disease.8
Risk factors. Premature atherosclerotic lesions have
been observed in children and young adults.9 The presence
of premature atherosclerosis may be differentially associ-
ated with established PVD risk factors. The established
PVD risk factors we considered included current smoking,
body mass index, history of CAD, self-reported diabetes,
hypertension, cholesterol, C-reactive protein, homocys-
teine, and kidney function. All models controlled for race/
ethnicity as a five-level categoric variable, conforming to
revised National Institutes of Health reporting standards.
For the purpose of reporting, race was defined as non-
Hispanic black vs all other. Hypertension status was defined
as history of hypertension by self-report or systolic blood
pressure 140 mm Hg or diastolic blood pressure 90
mm Hg on physical examination. CAD status was defined
as self-reported history of CAD, angina, or stroke. Respon-
dents not asked these questions in 1999-2000 were kept as
a separate category. The Cockroft-Gault formula was usedto calculate creatinine clearance standardized to body sur-
face area. Subjects were considered to have renal insuffi-
ciency if their creatinine clearance was 60 mL/
(min · 1.73 m2).
Statistical analysis. All statistical analyses used the svy
functions in STATA 8.2 (StataCorp, College Station,
Texas). These functions incorporate NHANES survey
weights, which reflect differential probability of selection
resulting from over-sampling of certain subgroups and are
adjusted for nonresponse. In addition, the svy functions
account for the stratification and clustering of observations
resulting from the complex NHANES sampling design,
ensuring correct estimation of standard errors, confidence
intervals, and P values.
In preliminary analysis, we compared PVD risk factors
by age category (60 vs 60), using F tests for categoric
variables, and svy linear regression models for continuous
measures. Both methods take account of weighting, strat-
ification, and clustering.
Differential associations between risk factors and prev-
alent PVD by age category were first explored by using a
Wald test for interaction between the risk factor and age
category in unadjusted logistic regression models. If the
interaction was significant at P .1, separate indicators for
this risk factor were incorporated into the multivariate
model for both the older and younger age categories. Risk
factors in which no interaction with age was seen in the
unadjustedmodel were assumed to have comparable effects
in both age strata and were included in the multivariate
model in their simplified form.
In the multivariate analysis, an initial regression model
was estimated including age, race/ethnicity, all risk factors
identified a priori, and the interactions identified in unad-
justed analysis. Backwards selection was then used to elim-
inate predictors and interactions with age with P  .1 after
adjustment.
In model checking, the linearity of the associations
between continuous predictors and PVD were examined
using piecewise linear splines. No departures from linearity
significant at P  .1 were found. We also assessed hetero-
geneity of risk factor effects by gender, and by age and
gender jointly, and no important additional interactions
were found.
RESULTS
Demographics. Results of the population characteris-
tics of the United States are summarized in Table I. Com-
parisons are made between members of the population
aged 60 years and 60 years. The younger population
had a higher percentage of men and blacks. Obesity, as
measured by BMI, was roughly equivalent in the two age
categories.
Premature PVD was found in 2.1%  0.3% of the
population 60 years, and PVD was found in 12.0% 
0.8% of the population 60 years. This corresponds to
approximately 1.44 million people with premature PVD.
On average, people60 years were less likely to have major
comorbid conditions, including hypertension, CAD, dia-
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 2 Lane et al 321betes, and chronic renal insufficiency. Younger patients
were more likely to be smokers, however.
Serologic risk factors for PVD, including serum con-
centrations of homocysteine, fibrinogen, creatinine, and
C-reactive protein, were all numerically higher in older
patients. Cholesterol levels were equivalent in the two
groups.
Bivariate analysis. Results of the bivariate analyses are
summarized in Tables II and III. In bivariate analyses,
adjusted only for age, all risk factors are predictive of PVD
with the exception of CAD, creatinine clearance, and BMI
(Table II). The strongest positive associations with PVD
were found with hypertension, smoking, and serum creat-
inine concentration.
Stratified bivariate analyses were then performed to
determine interaction between age (60 vs60 years) and
each risk factor (Table III). These reveal significant inter-
actions for CAD, creatinine, creatinine clearance, homocys-
teine, and fibrinogen (P  .10). For CAD, creatinine
clearance, and fibrinogen, the odds of PVD were increased
in the younger age category. In contrast, increased serum
homocysteine and creatinine clearance afforded higher
odds of PVD in the older age category. The most profound
interaction was seen with CAD, which was highly predictive
Table I. Population characteristics by age 60 or 60
years from NHANES, 1999-2002
Characteristic
Age 60
(n  2498)
Age 60
(n  2585) P
Mean age, y 48.6  0.2 70.3  0.2 0.001
Female (%) 50.3  1.0 55.0  0.8 0.002
Black (%) 9.9  1.2 7.6  1.2 0.007
Body mass index 28.2  0.2 28.0  0.1 0.050
Comorbid
conditions (%)
Peripheral
vascular
disease
2.1  0.2 12.0  0.8 0.001
Hypertension 29.8  1.4 65.1  1.1 0.001
Coronary artery
disease
5.1  0.7 17.9  1.2 0.001
Smoking 24.7  1.3 12.7  0.9 0.001
Diabetes 6.3  0.6 13.5  0.6. 0.001
Chronic renal
insufficiency
10.2  0.9 25.3  1.1 0.001
Laboratory values
(mg/dL)
Cholesterol 211.5  1.5 212.8  1.0 0.369
Homocysteine 8.4  0.1 10.0  0.1 0.001
Fibrinogen 351.5  3.4 386.8  3.1 0.001
Creatinine 0.82  0.01 0.91  .01 0.001
C-reactive
protein
0.41  0.02 0.51  .02 0.002
NHANES, National Health and Nutritional Survey; n, sample number of
NHANES participants.
Data are mean or percent  SE.
P values are 2 test for categoric variables and t test for continuous variables.
All values were calculated with the examination weight variable
(WTMEC4YR).of PVD in the younger age group (OR, 3.60; P .008) butwas only weakly associated with PVD in the older age group
(OR, 1.26; P  .367).
Multivariate analysis. After fitting the initial model, a
backward selection process eliminated both cholesterol
(P .33) and C-reactive protein (P .70). In addition, the
previously observed interaction between age and homocys-
teine had been attenuated, and homocysteine was retained
in the model as an unstratified predictor. The final multiple
logistic model is reported in Table IV. The strong interac-
tion seen with CAD remained in the final model, with CAD
conveying higher odds of PVD in the younger age group
(OR, 2.90 vs 1.26). Serum fibrinogen levels also were more
predictive of PVD in the younger age group. A 10-mg/dL
increase in fibrinogen was associated with a 7% increased
odds in subjects 60 years compared with a 4% increase in
patients60 years. In contrast, a decrease creatinine clear-
ance was more strongly associated with PVD in the older
age group, with a 10-unit decrease affording a 16% in-
creased odds of PVD. The association of creatinine clear-
ance with PVD was not significant in the younger age
group (OR, 1.02, P  .712).
Other significant predictors of PVD included hyperten-
sion (OR, 1.99; P .001), smoking (OR, 2.22; P .001),
and serum homocysteine (OR, 1.27; P  .067). Diabetes
(OR, 1.53, P  .104) was not independently predictive of
PVD but was retained in the model for face validity. Inter-
estingly, increased BMI (OR, 0.96; P  .003) was associ-
ated with a mild protective effect from PVD. However, this
may represent residual negative confounding after adjust-
ing for other factors such as hypertension.
DISCUSSION
We have found that premature PVD, defined as an ABI
0.9, affects only about 2% of the US population 60
years; however, this represents about 1.44 million Ameri-
Table II. Bivariate logistic regression analyses adjusted
for age (ABI 0.9)
Risk factor/predictor
OR of
PVD CI P
Smoking 2.60 1.98-3.41 .001
Hypertension 2.01 1.51-2.68 .001
Diabetes 1.79 1.20-2.69 .006
CAD 1.53 .91-2.58 .106
Creatinine 1.34 1.14-1.58 .001
C-reactive protein 1.21 1.11-1.34 .001
Cholesterol* 1.06 1.03-1.09 .001
Homocysteine 1.06 1.02-1.09 .001
Fibrinogen* 1.05 1.04-1.07 .001
Creatinine clearance† 0.99 .98-.99 .025
BMI 0.99 .96-1.03 .785
ABI,Ankle-brachial index;OR, odds ratio; PVD, peripheral vascular disease;
CI, confidence interval; CAD, coronary artery disease; BMI, body mass
index.
*Reported as a 10-mg/dL change in laboratory value.
†Reported as a 10-unit change in creatinine clearance (mL/
[min · 1.73m2]).cans at risk. Clearly, identification of these individuals
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ABI is associated with an increased risk of stroke, myocar-
dial infarction, cardiovascular death, and reduced func-
tional status.1-5 Additionally, previous studies have shown
that the development of PVD at an early age leads to a
particularly virulent course of disease, culminating in car-
diovascular morbidity, limb loss, and death.10 The aim of
this study was to consider the risk factors that are associated
with premature PVD in the US population.
Cardiovascular risk factors have traditionally been tar-
geted as the major determinants of atherosclerosis.11 These
factors include smoking, hypertension, diabetes, hypercho-
lesterolemia, and hyperlipidemia. Other prevalent diseases,
such as CAD12 and chronic renal insufficiency,13 have also
been used to effectively identify those at risk for premature
PVD. More recently, a number of novel serologic markers,
Table III. Bivariate logistic regression analyses Stratified
by Age 60 years (ABI0.9)
Risk factor/predictor OR CI P
P
(heterogeneity)
Significant
interactions
Coronary artery
disease
Age 60 3.60 1.43-9.03 .008 .026
Age 60 1.26 .75-2.10 .367
Creatinine clearance†
Age 60 1.00 .99-1.00 .725 .009
Age 60 0.99 .98-.99 .008
Creatinine
Age 60 1.00 .63-1.59 .986 .099
Age 60 1.46 1.12-1.91 .007
Homocysteine
Age 60 0.87 .44-1.72 .684 .011
Age 60 2.52 1.63-3.91 .001
Fibrinogen*
Age 60 1.08 1.05-1.10 .001 .060
Age 60 1.04 1.03-1.06 .001
Other predictors
BMI
Age 60 1.00 .94-1.07 .974 .809
Age 60 0.99 .96-1.03 .654
Cholesterol*
Age 60 1.00 .93-1.08 .969 .702
Age 60 1.02 .96-1.07 .610
Hypertension
Age 60 2.01 1.15-3.51 .016 .989
Age 60 2.01 1.53-2.65 .001
Smoking
Age 60 2.72 1.63-4.55 .001 .828
Age 60 2.52 1.74-3.67 .001
Diabetes
Age 60 1.56 .44-5.55 .477 .790
Age 60 1.86 1.25-2.77 .004
C-reactive protein
Age 60 11.52 1.61-82.59 .017 .560
Age 60 5.79 2.00-16.76 .002
ABI, Ankle-brachial index; OR, odds ratio; CI, confidence interval.
*Reported as a 10-mg/dL change in laboratory value.
†Reported as a 10-unit change in creatine clearance (mL/[min · 1.73m2])including C-reactive protein, lipoprotein A, fibrinogen,and homocysteine, have been used to identify high-risk
individuals.14 Increasing evidence supports the use of these
factors in screening and disease prevention; however, pre-
vious studies have failed tomeet consensus on which factors
to include for optimal detection of premature PVD.
To answer this question, we used data from the
NHANES 2000 survey. The strengths of this study design
include the use of a population-based data set. Survey
weights can be used tomake estimates about the prevalence
of PVD in the United States. The associations observed
between risk factors and premature PVD can be generalized
to the national population. The large sample size of this
survey allows for the detection of relatively small effect
sizes, which may uncover associations not appreciated in
smaller studies. Finally, the large number of covariates
collected by NHANES allows for the simultaneous consid-
eration of multiple variables.
One major finding of this study is that a history of CAD
is predictive of premature PVD in the US population 60
years of age. It is not surprising that atherosclerotic disease
in the peripheral vascular bed is found concomitantly with
disease in the coronary vascular bed; however, the strength
of the interaction between younger and older patients
deserves emphasis. In multivariate analysis, PVD is associ-
ated with other cardiovascular conditions in the younger
age group, but an association is lacking in the older popu-
Table IV. Multivariate logistic regression analyses for
peripheral vascular disease (ABI 0.9)
Risk factor OR CI P
P
(heterogeneity)
Significant
interactions
Coronary artery
disease
Age60 2.90 .86-9.80 0.084 .083
Age60 1.26 .75-2.10 0.367
Fibrinogen*
Age60 1.07 1.04-1.10 0.001 .034
Age60 1.03 1.01-1.05 0.001
Creatinine clearance†
Age60 1.02 .93-1.12 0.712 .006
Age60 1.16 1.08-1.25 0.001
Other significant
predictors:
Male gender 2.04 1.40-2.96 0.001
Hypertension 1.99 1.40-2.85 0.001
Smoking 2.22 1.47-3.37 0.001
BMI 0.96 .93-.98 0.003
Diabetes 1.53 .91-2.58 0.104
Homocysteine* .27 .98-1.65 0.067
ABI, Ankle-brachial index; OR, odds ratio; CI, confidence interval; BMI,
body mass index.
Significant predictors determined at P  .05
Significant interaction determined at P  .10.
Diabetes retained in the model for face validity.
*Reported as a 10-mg/dL change in laboratory value.
†Reported as a 10-unit change in creatinine clearance (mL/
[min · 1.73m2]).lation (P heterogeneity  .83). The premature develop-
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severe systemic involvement of the coronary and cerebral
vascular circulations. Because these patients are at high risk
for cardiovascular death, this provides an opportunity to
target young patients with a low ABI for screening and
secondary prevention efforts. Measurement of ABI in
young patients may improve the cardiac risk assessment
when added to information gained from the medical his-
tory.
In addition, we found interaction between the devel-
opment of premature PVD and elevated fibrinogen levels;
however, the magnitude of this association was modest. A
10-mg/dL increase in fibrinogen was associated with a 7%
increased odds in subjects 60 years compared with a 3%
increase in patients 60 years. This statistical finding may
be a result of our large sample size and does not argue for
wide-scale screening for high fibrinogen levels to detect
PVD. Among those with diagnosed PVD, however, the
detection of elevated fibrinogen levels may also lead to
secondary intervention.
Fibrates and niacin can lower fibrinogen levels.15 How-
ever, a recent randomized controlled trial examining the
effect of bezafibrate in patients with established PVD
showed no effect on incident coronary events or stroke
despite a 13% reduction in fibrinogen.16 This study did not
provide subgroup analysis of the fibrate effect in younger
and older patients.
In contrast, we found a decrease in creatinine clearance
is more predictive of PVD in the population 60 years of
age. A recent analysis using the NHANES data set13 found
the unadjusted odds of developing PVD in patients with
renal insufficiency was 9.7, with an odds ratio of 2.5 after
adjustment for age and other comorbidities. The higher
unadjusted association likely reflects more comorbidities,
such as diabetes and hypertension, among those with renal
insufficiency as well as a 20-year difference in mean age.
Our result supports the effect of renal insufficiency increas-
ing with age. One possibility is that prolonged renal insuf-
ficiency may cause vascular injury and predispose to the
development of PVD. This may be mediated by alterations
in metabolic pathways (calcium-phosphorus, homocys-
teine, lipoprotein) or alterations in inflammatory or coag-
ulation cascades.17
Finally, we identified other strong risk factors that
are independently associated with PVD, regardless of age
category. These include smoking and hypertension,
which are well-established risk factors for the develop-
ment of atherosclerotic disease. A weaker positive asso-
ciation was also seen with plasma homocysteine (P 
.067). Errors in homocysteine metabolism have been
associated with the development of atherosclerotic vas-
cular disease.18 A common mutation in the MTHFR
gene (5,10-methylenetetrahydrofolate reductase) leads
to moderate elevations of plasma homocysteine (about
25%), particularly in the low-folate state.19 Meta-analy-
ses have shown only weak evidence of the association
between homocysteine and atherosclerotic vascular dis-
ease in the general population.20 This weak association issupported in our population-based study. The effect of
high-dose folate supplementation in the prevention of
cardiovascular disease is currently under investigation in
multiple randomized trials.
The use of the NHANES data set has allowed us to
overcome the problem of selection bias found in smaller
studies by identifying risk factors for the development of
PVD representative in the national population. The nature
of this cross-sectional data set has limitations, however. The
data collected by NHANES is itself subject to selection bias
because not all the participants who were selected had the
lower extremity examination. Furthermore, the ABI exam-
ination is subject to measurement bias owing to operator
error or incompressibility of the lower extremity arteries.
Because the data are observational, causality between risk
factor and the development of PVD cannot be determined.
In addition, the data set is not longitudinal, so no estima-
tion of disease incidence is possible. Furthermore, associa-
tions can only be made on variables collected in the
NHANES database. Potentially important predictors of
PVD, such as lipoprotein (a),7 are not presently collected
by NHANES.
CONCLUSIONS
Despite these limitations, our findings have important
clinical implications. The association between PVD and
prevalent CAD has previously been recognized.5 In fact, a
decreased ABI has been shown to be one of the strongest
predictors of cardiovascular morbidity and all-cause mor-
tality.21 With noninvasive screening for PVD using ABI
measurement, subclinical cardiovascular disease can be in-
ferred and secondary intervention performed. Screening for
elevated levels of fibrinogen or homocysteine may also aid
in the detection of premature PVD. A screening study from
a high-risk cardiology clinic identified these factors as being
independently predictive of mortality after adjustment for
traditional (Framingham) risk factors.21 Screening among
such a highly selected population may help identify those
that would most benefit from secondary intervention.
Clinicians should be aware of the high risk of develop-
ing premature PVD in patients 60 years with coexisting
CAD or elevated fibrinogen. Screening by ABI measure-
ments in these patients would enhance the detection of
subclinical premature PVD and CAD and allow for second-
ary intervention.22
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Audience (unidentified speaker). Just one question. Why
did you pick age 60 as a definition for premature atherosclerosis? I
think in Valentine’s work it is age 50, and I know other authors
who have actually called it age 40, so it seems like the definition of
premature keeps getting older and older. Any answers about why
you did that?
Dr John Lane. Thank you for the question. Yes, as you are
familiar with the literature, Dr Valentine’s group actually a lot of
times would define this as age 45. One of the reasons we defined it
as age 60 is that some authors have used this in the past. It is kind
of a moving target of how and when you define premature periph-
eral vascular disease, and one of the reasons I did allow for a
roughly equal sample size in both the older and younger age
groups. We did look at different cut points, and it didn’t really
significantly change our findings by using a cutoff at age 45.
Dr Charles Andersen (Tacoma, Wash). I rise to suggest that
it may be time for a terminology change in our field. We talk about
peripheral vascular disease as if it were something separate, a
separate area of atherosclerosis. I would throw out a suggestion
that screening with ABIs is not about the legs at all. It is about early
detection of atherosclerotic vascular disease and then an aggressive
approach to a systemic disease. My question is if you pick up an
early abnormal ABI, what do you do from there?
Dr Lane. Thank you for the question and your observation. I
do think this is incredibly important. In fact, there was a recent
article in theAnnals of InternalMedicine out ofUCSF that showedfailure, so it seems that ABIs are becoming an incredibly powerful
marker, and you are right, it is not just for detecting peripheral
vascular disease, but finding for vascular disease in the entire body.
To your question, I think when you find a patient with an
abnormal ABI, this is your opportunity to afford early secondary
intervention. How this can be done is by altering risk factors,
including the treatment of hypertension, cholesterol, and diabetes,
and the new serologic risk factors that we were analyzing in the
study. I think we also have some evidence that there is medical
treatment for them. So I think this is a way that we can prevent
patients from coming to the operating table and trying to treat
these risk factors early when you identify them with an early
abnormal ABI.
Audience (unidentified speaker). Very nice presentation. If
you ask a practicing vascular surgeon what the greatest risk factors
are for the younger patients, it seems to me the no-brainers would
be patients who have type 1 or insulin-dependent diabetes and
patients on dialysis, chronic renal failure. I may have missed it in
your methodology, but were those patients excluded, or could you
explain how the data would be assessed that those patients would
not fall out in your analysis, because to me, those are the no-
brainers. These are the subtle risk factors that we don’t always
measure, but I would think that the highest risk would be in that
group of patients, and that is what our clinical experience is.
Dr Lane. Thank you. Yes, diabetes and dialysis are certainly
very important risk factors. Diabetes was included; however, we
did not—the data in NHANES was not stratified to type 1 versus
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Volume 44, Number 2 Lane et al 325type 2 diabetes—so, unfortunately, I can’t give you which type of
diabetes. Dialysis patients were not excluded from sampling in
NHANES. I did not present nor did I analyze the dialysis group
independently. One of the reasons was because even with the
sampling, there were 5000 patients in the sample. The occurrence
was only 2% in the younger age category and 12% in the older. If
you start breaking it down all the way to the number actually on
dialysis, the number of outcomes is going to be small in the age
category, and it might not have been powerful in the analysis so
that wasn’t performed, but, yes, we all know that is incredibly
important in developing premature disease.
Dr Christian Devirgilio (Los Angeles, Calif). I enjoyed your
presentation. Very nice work. I had sort of a practical question for
the family practitioner who might be looking to screen. Given that
hypertension and smoking were important risk factors in both old
and young, if they were to simply use smoking and hypertension as
a guide to getting the simple ABI, how many patients would be
missed if you did not use, say, the fibrinogen? In other words, is it
practical to be telling the family practitioner that they should be
screening fibrinogen when a simple ABI could be done just based
on smoking and hypertension?
Dr Lane. Thank you, Dr Devirgilio. Yes, very insightful.
When you are talking about screening a general population, cer-
tainly the strongest risk factors are the ones that aremost important
such as smoking and hypertension as well as diabetes. Whether
these serologic risk factors are really important in the general
population, it may not be clear, and certainly our data do not bear
that out. When you are talking about screening for those things, I
think it is more important in a high-risk population. There was a
paper out of The Cleveland Clinic that looked at screening for
these more subtle risk factors in patients that are extremely high
risk, such as referrals to a high-risk cardiology clinic, and in our
instance, maybe a referral to a vascular clinic. In those, the novel
risk factors did add something to the prediction, and again, it offers
an opportunity for treatment. So in a general population such as a
US population, which I am talking about here, I don’t think our
data support that this makes sense. I think you should concentrate
on the big risk factors such as smoking, hypertension, and diabetes,
but when you are looking at a referral population or a high-risk
population, I think in that case it makes sense and I think this
should be considered more closely in our peripheral vascular
patients in a future study.
Dr Thomas Rehring (Denver, Colo). I have one comment
and then a question for you. To Dr Andersen’s question, I mean
those patients who you identify with a diagnosis of PAD should
instantly be started on all secondary prevention strategies you
initiate in somebody with coronary artery disease, which would
include -blockade, ACE inhibitors, antiplatelet therapy, and
probably a statin to target an LDL of less than 100. I think it iswithin our purview and should be our recommendation, if we
don’t initiate therapy ourselves, that you should have a strong
letter back to that referring physician.
My question for you is this: we know that as many as two thirds
of patients in the elderly population that have a diagnosis of
peripheral arterial disease would be asymptomatic, that is, they can
be identified with a low ABI but may not have symptoms. It is my
impression that the younger population presents more commonly
with symptoms. Did they have data from this survey at all about
how many of these patients had symptoms?
Dr Lane. Yes. Thank you for your question. I certainly agree
with aggressive medical therapy for all people that have evidence of
vascular disease in any of the peripheral or coronary beds.
The lower extremity examination did have a symptom index,
or at least they ask if people are having claudication. Again, it
wasn’t very detailed and again, when you are talking about younger
patients with symptoms, when you are getting down to that small
of numbers, the analysis is not very powerful, so I did not include
that in the analysis; but, yes, the NHANES data set in the lower
extremity does ask if you have leg pain with walking and that is
something that could be analyzed in a future study.
Dr Preston Flanagin (Orange, Calif). Regarding the ankle-
brachial index being the best way to screen for peripheral vascular
disease in terms of having early intervention, I think that it is
actually a late manifestation if your ankle-brachial index is abnor-
mal. Most active patients that have an abnormal ankle-brachial
index are going to be symptomatic. If you have an abnormal
ankle-brachial index, you already have a critical stenosis somewhere
in your lower extremity vasculature. I have always been intrigued
with the use of that and I suspect it is mostly for cost reasons, but
it seems to me that duplex scanning, as we do for the carotids and
as we do for screening for abdominal aortic aneurysms, would be a
lot more effective in finding earlier peripheral vascular disease and
therefore allow for earlier and hopefully more effective interven-
tion.
Dr Lane. Thank you for your comment. We did use a very
somewhat high cut point. Most of us would not consider treating
a patient with an ABI of 0.9 unless they are very symptomatic from
that, which is hard to imagine, but certainly when you are talking
about ABIs in the lower category certainly they do also—say if you
use a cutoff of 0.5—they all have very profound peripheral and
possibly atherosclerotic disease in other vascular beds. Certainly,
this study does not look at duplex scanning as a sensitive marker.
People have tried to do this looking in the carotid circulation and
measuring intimal-to-medial thickness as trying to be an early
marker. Certainly, that is something important. People have tried
to use this as a predictive tool; however, we did not use this in the
study, and I don’t have any data to present that for the group.
